FDA Not Ready For The Nanotechnology Surge; Infrastructure - Not Technical Capability - Is The Challenge, Hamburg Says
Executive Summary
FDA Commissioner Margaret Hamburg said the agency's infrastructure is not where it needs to be in order to pursue nanotechnology initiatives
You may also be interested in...
Nanopharma Cerulean Advances Cancer Particle, Looks Ahead To siRNA
Nanotech platform company Cerulean Pharma Inc. has a high-quality problem. The Cambridge, Mass., start-up is poised to take its lead candidate into Phase IIb cancer trials, but the young company must choose among several cancer types in which the nanoparticle shows go-ahead activity
Nanopharma Cerulean Advances Cancer Particle, Looks Ahead To siRNA
Nanotech platform company Cerulean Pharma Inc. has a high-quality problem. The Cambridge, Mass., start-up is poised to take its lead candidate into Phase IIb cancer trials, but the young company must choose among several cancer types in which the nanoparticle shows go-ahead activity
Mega scale-up of nanotechnology research budget mulled
FDA could certainly use the additional $25 million per year for nanotechnology research that Sen. Mark Pryor, D-Ark., has proposed to authorize for the next five years, Commissioner Margaret Hamburg told the Senate Appropriations Committee March 9. Hamburg was there to defend the agency's fiscal year 2011 budget request, which includes $7 million for nanotechnology-related regulatory science activities. Much of the additional research the senator from Arkansas proposed would take place at the agency's National Center for Toxicological Research in Jefferson, Ark. When Pryor asked if FDA could spend the extra $25 million wisely, Hamburg assured him that it's a "very, very important emerging technology" and that "we always have to evolve our capabilities as emerging technologies also evolve" (see "The Pink Sheet," March 15, 2010